NK Cell Expansion Kit

Catalog #
78927
$900 *
Size: 1 Kit
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The NK Cell Expansion Kit is suitable for the ex vivo culture and expansion of human natural killer (NK) cells. It contains engineered Growth-Arrested NK Feeder Cells and NK Cell Basal Medium. The Growth-Arrested NK Feeder Cells are K562 cells engineered to express membrane bound IL-21, and other components, to drive the robust activation and expansion of NK cells.  The kit provides enough growth-arrested feeder cells for a starter population of 1 million purified NK cells or PBMC cells.

Product Info
Storage and Usage
Citations
Materials Required But Not Supplied
Name Ordering Information
Human PBMCs BPS Bioscience #79059
Human Peripheral Blood NK Cells, Frozen BPS Bioscience #78798
Anti-NCAM1 Antibody, PE-Labeled BPS Bioscience #101673
Anti-CD3 Antibody, FITC-Labeled BPS Bioscience #102008
500 x CFSE BPS Bioscience #82177
1000x 7-AAD BPS Bioscience #82178
K562  ATCC #CCL-243
eGFP/Firefly Luciferase K562 Cell Line BPS Bioscience #78911
eGFP/Firefly Luciferase RS4; 11 Cell Line  BPS Bioscience #78926
Clear-bottom, white 96-well tissue culture-treated plate Corning #3610
U-bottomed 96-well plate Corning #3799
ONE-Step™ Luciferase Assay System BPS Bioscience #60690
Thaw Medium 2 BPS Bioscience #60184
Luminometer  
Format
Catalog #  Name  Amount Storage
78912 Growth-Arrested NK Feeder Cells 2 million cells/ vial x 5 vials  Liquid Nitrogen
82164  NK Cell Basal Medium 500 ml 4°C
90184 Human Interleukin-2 10 µg -20°C 
Background

NK (natural killer) cells are part of the innate immune system. They function in a histocompatibility complex-independent mode and derive from the hematopoietic lineage. They are the first line of defense against cancer. Expression of marker CD56 correlates with NK cell functionality: the CD56bright subset accounts for about 5% of the population and is less cytotoxic than the CD56dim subset.  Cytotoxicity can happen by the release of perforin and granzyme, while activation by KARs (killer activating receptors) leads to release of Fas Ligand, TRAIL (TNF-related apoptosis-inducing ligand) and TNFα (tumor necrosis factor-alpha). In a suppressive tumor microenvironment, NK cells can become inhibited and unable to fight cancer cells. Several clinical trials have focused on using ex vivo generated NK cells alone or in combination with other approaches. NK cells can be generated ex vivo from peripheral blood, umbilical cord blood, iPS cells or immortalized NK cell lines. The ability to generate a number of pure cells high enough for human dosage often requires the use of growth factors such as IL-2 (interleukin 2) or IL-15, and feeder cells. The use of NK cells or CAR (chimeric antigen receptor)-NK cells is an expanding area holding great promise in cancer therapy.

References

Du N., et al., 2021 Cancers (Basel) 13 (16): 4129.